



NEWS RELEASE

Cognetivity Neurosciences CEO to Deliver Keynote Speech at Collision 2022 in Toronto

Dr. Sina Habibi to Present on the HealthConf Stage at Collision Conference, One of the World's Largest Technology Conferences

Vancouver, British Columbia, June 16, 2022 – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; OTCQB: CGNSF; FWB: 1UB), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its Co-founder and Chief Executive Officer (“CEO”), Dr. Sina Habibi will deliver a keynote presentation at Collision 2022 (“**Collision**” or the “**Conference**”) on June 23, 2022.

“It is an honour to be asked to deliver a keynote at one of the world’s most renowned innovation events,” said Dr. Sina Habibi, CEO of Cognetivity Neurosciences. “I’m excited to have such an incredible platform to share Cognetivity’s story and our goals to help shape the future of healthcare,” added Dr. Habibi.

Scheduled to appear on the HealthConf stage, Dr. Habibi’s talk entitled “Bringing Dementia Detection into the Digital Age” will walk attendees through the founding story behind Cognetivity’s pioneering brain health screening technology, CognICA™, and outline the significant implications of AI-enabled early detection of brain health issues – including dementia and Alzheimer’s – on patient outcomes and global costs of care.

According to the Lancet Commission, almost one billion people worldwide suffer from a mental disorder and the estimated costs of these disorders is estimated to have a global economic cost of US\$16 trillion by 2030¹. Early detection of brain health disorders has the potential to significantly reduce costs of care while improving patient outcomes. Cognetivity’s CognICA™ technology is a unique and highly scalable software-as-a-service solution able to accurately detect the earliest stages of the majority of major brain health disorders.

The sold out Collision 2022 event, to be held in Toronto, will host approximately 35,000 attendees and feature over 600 speakers, gathering the most prestigious names in technology, business, sport and entertainment as well as over 1,200 journalists from publications including Bloomberg, Financial Times, Forbes, CNN Business, CNBC, and the Wall Street Journal.

More information about Collision 2022 can be found on its website: <https://collisionconf.com>.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA™ uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. CognICA™ is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

For more information, please visit: www.cognetivity.com or contact: info@cognetivity.com
For media enquiries, please contact: Josh Stanbury | josh@sispr.co | 416-628-7441

ON BEHALF OF THE BOARD

"Sina Habibi"
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

ENDNOTES:

1. The Lancet Commission on Health and Global Mental Sustainable Development, 2018.

SOURCE: Cognetivity Neurosciences Ltd.